Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky maintains an Outperform rating on Anika Therapeutics (NASDAQ:ANIK) with a $37 price target.
August 09, 2024 | 9:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barrington Research analyst Michael Petusky maintains an Outperform rating on Anika Therapeutics with a $37 price target.
The reaffirmation of an Outperform rating and a $37 price target by Barrington Research is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100